HY000102

N/A

Report date: 2025/04/22 20:00:06

Base Information

Drug NameHY000102
Drug Alias Name重组抗NKG2A人源化单克隆抗体注射液HY-0102HY-000102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionNK cell lectin-like receptor subfamily C member 1 antagonists
TargetsNK cell lectin-like receptor subfamily C member 1
Therapy Area/IndicationsSolid tumoursPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai HyaMab Biotech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai HyaMab Biotech Co LtdYL-Pharma
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A